Clinicopathological Characteristics in Combined Hepatocellular-Cholangiocarcinoma: A Single Center Study in Korea

被引:22
|
作者
Park, Hana [1 ]
Choi, Ki Hong [2 ,3 ]
Choi, Sae-Byeol [4 ]
Choi, Jong Won [1 ]
Kim, Do Young [1 ,3 ,5 ]
Ahn, Sang Hoon [1 ,3 ,5 ,6 ]
Kim, Kyung Sik [2 ,3 ]
Choi, Jin Sub [2 ,3 ]
Han, Kwang-Hyub [1 ,3 ,5 ,6 ]
Chon, Chae Yoon [1 ,3 ,5 ]
Park, Jun Yong [1 ,3 ,5 ]
机构
[1] Yonsei Univ, Coll Med, Dept Internal Med, Seoul 120752, South Korea
[2] Yonsei Univ, Coll Med, Dept Surg, Seoul 120752, South Korea
[3] Yonsei Univ, Coll Med, Liver Canc Special Clin, Seoul 120752, South Korea
[4] Korea Univ, Coll Med, Dept Surg, Seoul 136705, South Korea
[5] Liver Cirrhosis Clin Res Ctr, Seoul, South Korea
[6] Brain Korea 21 Project Med Sci, Seoul, South Korea
关键词
Combined hepatocellular and cholangiocarcinoma; hepatocellular carcinoma; cholangiocarcinoma; PROGNOSTIC-FACTORS; CARCINOMA; FEATURES; RESECTION; CT;
D O I
10.3349/ymj.2011.52.5.753
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose: Combined hepatocellular-cholangiocarcinoma (CHCC) is an uncommon form of cancer, and its clinicopathological features have rarely been reported in detail. This study was undertaken to evaluate the clinicopathological characteristics and prognostic factors of CHCC. Materials and Methods: The clinicopathological features of patients diagnosed with CHCC at Severance Hospital between January 1996 and December 2007 were retrospectively studied by comparing them with the features of patients with hepatocellular carcinoma (HCC) or cholangiocarcinoma (CC) who had undergone a hepatic resection during the same period. Results: Forty-three patients diagnosed with CHCC were included in this study (M : F=35 : 8, median age, 55 years). According to the parameters of the American Joint Committee on Cancer staging, there were 6 (14.0%), 9 (20.9%), 25 (58.1%), and 3 (7.0%) patients with stages I, II, III, and IV cancer, respectively. Thirty-two of the 43 patients underwent resection with curative intent. After resection, 27 patients (84.4%) had tumor recurrence during the follow-up period of 18 months (range: 6-106 months), and the median time to recurrence was 13 months. Overall median survival periods after hepatic resection of CHCC, HCC and CC were 34, 103 and 38.9 months, respectively (p<0.001). The median overall survival for all patients with CHCC was 21 months, and the 5-year survival rate was 18.1%. The presence of portal vein thrombosis and distant metastasis were independent prognostic factors of poor survival. Conclusion: Even after curative hepatic resection, the presence of a cholangiocellular component appeared to be a poor prognostic indicator in patients with primary liver cancer.
引用
下载
收藏
页码:753 / 760
页数:8
相关论文
共 50 条
  • [41] Is nestin a diagnostic marker for combined hepatocellular-cholangiocarcinoma?
    Sasaki, M.
    Sato, Y.
    Nakanuma, Y.
    HISTOPATHOLOGY, 2022, 80 (05) : 859 - 868
  • [42] Imaging features of combined hepatocellular-cholangiocarcinoma on contrast-enhanced ultrasound: correlation with clinicopathological findings
    Ye, J.
    Xie, X.
    Lin, Y.
    Liu, B.
    Wang, W.
    Huang, X.
    Huang, G.
    CLINICAL RADIOLOGY, 2018, 73 (03) : 237 - 243
  • [43] Epigenetic regulation of combined hepatocellular-cholangiocarcinoma subtypes
    Schachtschneider, Kyle M.
    Lokken, Ryan Peter
    Huang, Yu-Hui
    Guzman, Grace
    Schook, Lawrence B.
    Gaba, Ron C.
    CANCER RESEARCH, 2019, 79 (13)
  • [44] EVIDENCE FOR A HEPATOCELLULAR LINEAGE IN A COMBINED HEPATOCELLULAR-CHOLANGIOCARCINOMA OF TRANSITIONAL TYPE
    FISCHER, HP
    DOPPL, W
    OSBORN, M
    ALTMANNSBERGER, M
    VIRCHOWS ARCHIV B-CELL PATHOLOGY INCLUDING MOLECULAR PATHOLOGY, 1988, 56 (02) : 71 - 76
  • [45] Combined hepatocellular-cholangiocarcinoma: biology, diagnosis, and management
    Ye, Liangtao
    Schneider, Julia S. S.
    Ben Khaled, Najib
    Schirmacher, Peter
    Seifert, Carolin
    Frey, Lea
    He, Yulong
    Geier, Andreas
    De Toni, Enrico N. N.
    Zhang, Changhua
    Reiter, Florian P. P.
    LIVER CANCER, 2024, 13 (01) : 6 - 28
  • [46] Differential miRNA Analysis of Combined Hepatocellular-Cholangiocarcinoma in Comparison to Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: Pilot Study
    Malik, Preeti
    Huang, Yan
    Castrodad-Rodriguez, Carlos
    Lin, Juan
    Loudig, Olivier
    Bhalla, Amarpreet
    MODERN PATHOLOGY, 2022, 35 (SUPPL 2) : 1137 - 1139
  • [47] Differential miRNA Analysis of Combined Hepatocellular-Cholangiocarcinoma in Comparison to Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: Pilot Study
    Malik, Preeti
    Huang, Yan
    Castrodad-Rodriguez, Carlos
    Lin, Juan
    Loudig, Olivier
    Bhalla, Amarpreet
    LABORATORY INVESTIGATION, 2022, 102 (SUPPL 1) : 1137 - 1139
  • [48] Breast Metastasis From a Combined Hepatocellular-Cholangiocarcinoma
    Silva, Marco
    Coelho, Rosa
    Rios, Elisabete
    Gomes, Sara
    Carneiro, Fatima
    Macedo, Guilherme
    ACG CASE REPORTS JOURNAL, 2019, 6 (04)
  • [50] Clinicopathological characteristics of 15 patients with combined hepatocellular carcinoma and cholangiocarcinoma
    Zuo, Huai-Quan
    Yan, Lu-Nan
    Zeng, Yong
    Yang, Jia-Ying
    Luo, Hong-Zhi
    Liu, Jiang-Wen
    Zhou, Li-Xin
    HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, 2007, 6 (02) : 161 - 165